Protagonist Therapeutics, Inc Increase (Decrease) in Income Taxes Payable
Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Income Taxes Payable of -$2.69 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-08-05
- Protagonist Therapeutics, Inc increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was $0.00.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes payable for the quarter ending 2025-06-30 was -$1.89M.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes payable for the quarter ending 2025-03-31 was -$800.00K, a 124.05% decline year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes payable for fiscal 2025 was -$2.69M, a 200.00% decline from fiscal 2024.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes payable for fiscal 2024 was $2.69M.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | -$1.89M derived: sum of 3 quarters · filed 2026-08-05 | -$2.69M 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.89M derived: sum of 2 quarters · filed 2026-08-05 | -$2.69M 10-Q · filed 2025-11-06 | -$1.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.69M 10-Q · filed 2026-08-05 | -$1.05M derived: sum of 3 quarters · filed 2026-08-05 | -$2.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$800.00K 10-Q · filed 2026-05-05 | $840.00K derived: sum of 2 quarters · filed 2026-05-05 | -$761.00K derived: sum of 3 quarters · filed 2026-05-05 | -$1.44M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $39.00K derived: sum of 2 quarters · filed 2026-02-25 | -$637.00K derived: sum of 3 quarters · filed 2026-02-25 | $2.69M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.28M derived: sum of 2 quarters · filed 2025-11-06 | $1.05M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$676.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.65M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $3.33M 10-Q · filed 2025-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |